Lubricin as a Therapeutic and Potential Biomarker in Sepsis

Crit Care Clin. 2020 Jan;36(1):55-67. doi: 10.1016/j.ccc.2019.08.005. Epub 2019 Oct 21.

Abstract

Proteoglycan 4 (or lubricin), a mucin-like glycoprotein, was originally classified as a lubricating substance within diarthrodial joints. More recently, lubricin has been found in other tissues and has been implicated in 2 inflammatory pathways within the cell, via the Toll-like receptors (TLRs) and CD44. Lubricin is an antagonist of TLR2 and TLR4, and appears to enter cells via the CD44 receptor. Because of lubricin's action on these receptors, downstream processes of inflammation are halted, thereby preventing release of cytokines (a hallmark of inflammation and sepsis) from the cell, indicating lubricin's role as a biomarker and possible therapeutic for sepsis.

Keywords: CD44; Inflammasome; Inflammation; Lubricin; NF-κB; PRG4; Toll-like receptors.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Biomarkers / blood*
  • Glycoproteins / blood*
  • Humans
  • Hyaluronan Receptors / blood
  • Inflammation / blood*
  • Inflammation / diagnosis
  • Sepsis / blood*
  • Sepsis / diagnosis*
  • Sepsis / drug therapy*
  • Toll-Like Receptor 1 / blood

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • Glycoproteins
  • Hyaluronan Receptors
  • TLR1 protein, human
  • Toll-Like Receptor 1
  • lubricin